December 12, 2018
1 min read

Europe’s Luxturna approval tops November retina news

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The European Commission’s approval of Luxturna for inherited retinal disease was the most-read retina-related article on in November. Other top news included clinical trial updates from Clearside and Adverum.

Here are the top five most-read retina articles of the month:


Europe approves first gene therapy for retinal dystrophy

On Nov. 23, the European Commission approved the first gene therapy for the treatment of inherited retinal disease related to a mutation of the RPE65 gene. Luxturna will be authorized in all 28 EU member states as well as Norway, Iceland and Lichtenstein. Read more.


Zimura-Lucentis combination safe in wet AMD patients in phase 2a trial

Zimura, a complement factor C5 inhibitor, was found to be well tolerated in combination with Lucentis in a phase 2a clinical trial. Read more.


First patient dosed in Adverum wet AMD gene therapy trial

The multicenter, open-label OPTIC phase 1 trial is designed to assess the safety and tolerability of a single intravitreal administration of ADVM-022. Eighteen patients will be enrolled in the trial, which will evaluate three doses of the therapy. Read more.


Clearsides retinal vein occlusion therapy fails to meet phase 3 endpoint

The multicenter, multi-country, randomized, masked phase 3 SAPPHIRE trial compared Xipere — formerly called suprachoroidal CLS-TA, a proprietary suspension of triamcinolone acetonide — used together with intravitreal Eylea (aflibercept, Regeneron) to Eylea monotherapy. Read more.


Ophthotech acquires Versant Ventures-backed Inception 4

Ophthotech Corp. has acquired Inception 4 Inc. and its small molecule inhibitors of HtrA1, which are under development for the treatment of a range of retinal diseases. Read more.